TrialJournal for immunotherapy of cancer2021

Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.

Paul Nghiem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.